Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Usana Health Sciences (USNA) EBT (2016 - 2025)

Historic EBT for Usana Health Sciences (USNA) over the last 16 years, with Q3 2025 value amounting to $1.8 million.

  • Usana Health Sciences' EBT fell 9035.9% to $1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $47.8 million, marking a year-over-year decrease of 4836.54%. This contributed to the annual value of $76.4 million for FY2024, which is 2547.7% down from last year.
  • Latest data reveals that Usana Health Sciences reported EBT of $1.8 million as of Q3 2025, which was down 9035.9% from $18.8 million recorded in Q2 2025.
  • Over the past 5 years, Usana Health Sciences' EBT peaked at $54.3 million during Q3 2021, and registered a low of $1.8 million during Q3 2025.
  • In the last 5 years, Usana Health Sciences' EBT had a median value of $26.6 million in 2023 and averaged $26.9 million.
  • As far as peak fluctuations go, Usana Health Sciences' EBT surged by 3584.63% in 2021, and later plummeted by 9035.9% in 2025.
  • Over the past 5 years, Usana Health Sciences' EBT (Quarter) stood at $40.4 million in 2021, then crashed by 43.49% to $22.8 million in 2022, then rose by 16.7% to $26.6 million in 2023, then plummeted by 60.81% to $10.4 million in 2024, then tumbled by 82.8% to $1.8 million in 2025.
  • Its EBT stands at $1.8 million for Q3 2025, versus $18.8 million for Q2 2025 and $16.7 million for Q1 2025.